Published in:
Open Access
01-11-2017 | Original Article
Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
Authors:
Frida Ewald Sander, Malin Nilsson, Anna Rydström, Johan Aurelius, Rebecca E. Riise, Charlotta Movitz, Elin Bernson, Roberta Kiffin, Anders Ståhlberg, Mats Brune, Robin Foà, Kristoffer Hellstrand, Fredrik B. Thorén, Anna Martner
Published in:
Cancer Immunology, Immunotherapy
|
Issue 11/2017
Login to get access
Abstract
Regulatory T cells (T
regs) have been proposed to dampen functions of anti-neoplastic immune cells and thus promote cancer progression. In a phase IV trial (Re:Mission Trial, NCT01347996,
http://www.clinicaltrials.gov) 84 patients (age 18–79) with acute myeloid leukemia (AML) in first complete remission (CR) received ten consecutive 3-week cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose interleukin-2 (IL-2) to prevent relapse of leukemia in the post-consolidation phase. This study aimed at defining the features, function and dynamics of Foxp3
+CD25
highCD4
+ T
regs during immunotherapy and to determine the potential impact of T
regs on relapse risk and survival. We observed a pronounced increase in T
reg counts in peripheral blood during initial cycles of HDC/IL-2. The accumulating T
regs resembled thymic-derived natural T
regs (nT
regs), showed augmented expression of CTLA-4 and suppressed the cell cycle proliferation of conventional T cells ex vivo. Relapse of AML was not prognosticated by T
reg counts at onset of treatment or after the first cycle of immunotherapy. However, the magnitude of T
reg induction was diminished in subsequent treatment cycles. Exploratory analyses implied that a reduced expansion of T
regs in later treatment cycles and a short T
reg telomere length were significantly associated with a favorable clinical outcome. Our results suggest that immunotherapy with HDC/IL-2 in AML entails induction of immunosuppressive T
regs that may be targeted for improved anti-leukemic efficiency.